Literature DB >> 19022302

HIV-1 Tat C-terminus is cleaved by calpain 1: implication for Tat-mediated neurotoxicity.

Giovanni Passiatore1, Slava Rom, Davide Eletto, Francesca Peruzzi.   

Abstract

HIV-Encephalopathy (HIVE) is a common neurological disorder associated with HIV-1 infection and AIDS. The activity of the HIV trans-activating protein Tat is thought to contribute to neuronal pathogenesis. While Tat proteins from primary virus isolates consist of 101 or more amino acids, 72 and 86 amino acids forms of Tat are commonly used for in vitro studies. Although Tat72 contains the minimal domain required for viral replication, other activities of Tat appear to vary according to its length, sub-cellular localization, cell type and the stage of cellular differentiation. In this study, we investigated the stability of intracellular Tat101 during proliferation and differentiation of neuronal cells in culture. We have utilized rat neuronal progenitors as a model of neuronal cell proliferation and differentiation, as well as rat primary cortical neurons as a model of fully differentiated cells. Our results indicate that, upon internalization, Tat101 was degraded more rapidly in proliferating cells than in cells which either underwent neuronal differentiation or were fully differentiated. Intracellular degradation of Tat was prevented by the calpain 1 inhibitor, ALLN, in both proliferating and differentiated cells. Inhibition of calpain 1 by calpastatin peptide also prevented Tat cleavage. In vitro calpain digestion and mass spectrometry analysis further demonstrated that the sequence of Tat sensitive to calpain cleavage was located in the C-terminus of this viral protein, between amino acids 68 and 69. Moreover, cleavage of Tat101 by calpain 1 increased neurotoxic effect of this viral protein and presence of the calpain inhibitor protected neuronal cells from Tat-mediated toxicity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19022302      PMCID: PMC2704945          DOI: 10.1016/j.bbamcr.2008.10.010

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  41 in total

1.  A protein-based therapeutic for human cytomegalovirus infection.

Authors:  F Jean; L Thomas; S S Molloy; G Liu; M A Jarvis; J A Nelson; G Thomas
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-14       Impact factor: 11.205

2.  Probability-based protein identification by searching sequence databases using mass spectrometry data.

Authors:  D N Perkins; D J Pappin; D M Creasy; J S Cottrell
Journal:  Electrophoresis       Date:  1999-12       Impact factor: 3.535

3.  HIV-1 Tat causes apoptotic death and calcium homeostasis alterations in rat neurons.

Authors:  R Bonavia; A Bajetto; S Barbero; A Albini; D M Noonan; G Schettini
Journal:  Biochem Biophys Res Commun       Date:  2001-10-26       Impact factor: 3.575

Review 4.  Calpain and caspase: can you tell the difference?

Authors:  K K Wang
Journal:  Trends Neurosci       Date:  2000-01       Impact factor: 13.837

5.  Recombinant human immunodeficiency virus type 1 genomes with tat unconstrained by overlapping reading frames reveal residues in Tat important for replication in tissue culture.

Authors:  C Neuveut; K T Jeang
Journal:  J Virol       Date:  1996-08       Impact factor: 5.103

6.  Synergistic neurotoxicity by human immunodeficiency virus proteins Tat and gp120: protection by memantine.

Authors:  A Nath; N J Haughey; M Jones; C Anderson; J E Bell; J D Geiger
Journal:  Ann Neurol       Date:  2000-02       Impact factor: 10.422

7.  HIV-1 Tat through phosphorylation of NMDA receptors potentiates glutamate excitotoxicity.

Authors:  N J Haughey; A Nath; M P Mattson; J T Slevin; J D Geiger
Journal:  J Neurochem       Date:  2001-08       Impact factor: 5.372

8.  Human immunodeficiency virus type 1 protease regulation of tat activity is essential for efficient reverse transcription and replication.

Authors:  Ann Apolloni; C William Hooker; Johnson Mak; David Harrich
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

9.  MCP-1 (CCL2) protects human neurons and astrocytes from NMDA or HIV-tat-induced apoptosis.

Authors:  E A Eugenin; T G D'Aversa; L Lopez; T M Calderon; J W Berman
Journal:  J Neurochem       Date:  2003-06       Impact factor: 5.372

10.  Inhibition of furin-mediated processing results in suppression of astrocytoma cell growth and invasiveness.

Authors:  Javier Mercapide; Ricardo Lopez De Cicco; Daniel E Bassi; Javier S Castresana; Gary Thomas; Andres JP Klein-Szanto
Journal:  Clin Cancer Res       Date:  2002-06       Impact factor: 12.531

View more
  9 in total

1.  Stability of HIV-1 subtype B and C Tat is associated with variation in the carboxyl-terminal region.

Authors:  Xuechao Zhao; Lingyu Qian; Deyu Zhou; Di Qi; Chang Liu; Xiaohong Kong
Journal:  Virol Sin       Date:  2016-03-21       Impact factor: 4.327

Review 2.  Fate of microglia during HIV-1 infection: From activation to senescence?

Authors:  Natalie C Chen; Andrea T Partridge; Christian Sell; Claudio Torres; Julio Martín-García
Journal:  Glia       Date:  2016-11-26       Impact factor: 7.452

3.  Human immunodeficiency virus type 1 (HIV-1) transactivator of transcription through its intact core and cysteine-rich domains inhibits Wnt/β-catenin signaling in astrocytes: relevance to HIV neuropathogenesis.

Authors:  Lisa J Henderson; Amit Sharma; Maria Chiara G Monaco; Eugene O Major; Lena Al-Harthi
Journal:  J Neurosci       Date:  2012-11-14       Impact factor: 6.167

4.  HIV-1-Tat Protein Inhibits SC35-mediated Tau Exon 10 Inclusion through Up-regulation of DYRK1A Kinase.

Authors:  Ferdous Kadri; Marco Pacifici; Anna Wilk; Amanda Parker-Struckhoff; Luis Del Valle; Kurt F Hauser; Pamela E Knapp; Christopher Parsons; Duane Jeansonne; Adam Lassak; Francesca Peruzzi
Journal:  J Biol Chem       Date:  2015-11-03       Impact factor: 5.157

5.  HIV-1 protein Tat produces biphasic changes in NMDA-evoked increases in intracellular Ca2+ concentration via activation of Src kinase and nitric oxide signaling pathways.

Authors:  Kelly A Krogh; Nicole Wydeven; Kevin Wickman; Stanley A Thayer
Journal:  J Neurochem       Date:  2014-04-19       Impact factor: 5.372

6.  Modulation of the stability and activities of HIV-1 Tat by its ubiquitination and carboxyl-terminal region.

Authors:  Linlin Zhang; Juan Qin; Yuanyuan Li; Jian Wang; Qianqian He; Jun Zhou; Min Liu; Dengwen Li
Journal:  Cell Biosci       Date:  2014-10-07       Impact factor: 7.133

Review 7.  HIV-1 Tat inhibits EAAT-2 through AEG-1 upregulation in models of HIV-associated neurocognitive disorder.

Authors:  Xiang Ye; Yu Zhang; Qiping Xu; Honghua Zheng; Xiaoyan Wu; Jinhua Qiu; Zhou Zhang; Wei Wang; Yiming Shao; Hui Qin Xing
Journal:  Oncotarget       Date:  2017-06-13

8.  Cross-inhibition of pathogenic agents and the host proteins they exploit.

Authors:  Leeor Zilbermintz; William Leonardi; Sharon H Tran; Josue Zozaya; Alyssa Mathew-Joseph; Spencer Liem; Anastasia Levitin; Mikhail Martchenko
Journal:  Sci Rep       Date:  2016-10-05       Impact factor: 4.379

9.  In vitro models of HIV-1 infection of the Central Nervous System.

Authors:  Celeste Faia; Karlie Plaisance-Bonstaff; Francesca Peruzzi
Journal:  Drug Discov Today Dis Models       Date:  2019-12-20
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.